VK2735
VENTURE
Viking Therapeutics · Phase 2 · Completed · Enrollment 176
The paper states the 2.5 mg and 15 mg ends of the weekly range, and the placebo result. It does not state each intermediate dose in the abstract cited here, so those registry arms stay n/r.
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| VK2735 (Placebo) | Population n/r | n/r | n/r | n/r | n/r |
| VK2735 (Dose #1) | Population n/r | n/r | n/r | n/r | n/r |
| VK2735 (Dose #2) | Population n/r | n/r | n/r | n/r | n/r |
| VK2735 (Dose #3) | Population n/r | n/r | n/r | n/r | n/r |
| VK2735 (Dose #4) | Population n/r | n/r | n/r | n/r | n/r |
| VK2735 2.5 mg | Obesity, no T2D | 2.5 mg | 13 | n/r | -9.1% at week 13 |
| VK2735 15 mg | Obesity, no T2D | 15 mg | 13 | n/r | -14.7% at week 13 |
| Placebo 13 weeks | Obesity, no T2D | n/r | 13 | n/r | -1.7% at week 13 |